Skip to contentE
Endovia Health Sciences, Inc.
E
EDVAEndovia Health Sciences, Inc. Q3 2021 · 10-Q
Revenue$2.83M$2.83M+180.0% vs Q3 2020 Net Income-$12.17M-$12.17MN/M vs Q3 2020 EPS, diluted—
Gross Profit$819,849+138.4% Operating Income-$12,072,230N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endovia Health Sciences, Inc. · CIK 1553788 · Engraved from SEC EDGAR
Operating Cash Flowderived-$3,942,175N/M Margins · derivedGross margin29.0%−5.1 pt vs Q3 2020
Operating margin-427.0%−212.7 pt vs Q3 2020
Net margin-430.4%−224.0 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 15, 2021 · 46 d after period end